Q32 Bio Inc. (QTTB) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 9, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q2 FY2026, filed Aug 5, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the QTTB SEC filings page.
Q32 Bio Inc. (QTTB) reported $53.7M in revenue for fiscal year 2025. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 9 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Q32 Bio's 2025 statements show a sharp reported earnings turnaround, but cash flow still moved opposite to profit as the business changed scale.
The unusual split between 2025 net income of$29.8M and operating cash flow of-$33.5M means reported profit did not convert into cash. Compared with 2023 operating cash flow of-$18.7M , the latest result still describes a cash-consuming model despite positive accounting earnings.
The reported liquidity comparison equaled 17.3 months of the latest annual operating outflow, while a 4.9x current ratio and 0.5x debt-to-equity ratio indicate substantial short-term coverage without a heavily leveraged balance sheet.
Reported revenue reached
Financial Health Signals
Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Q32 Bio Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Q32 Bio Inc. held $48.3M in cash, cash equivalents and investments at the end of fiscal year 2025, and its operations used $33.5M of cash that year. Cash Runway ranks emerging companies on the size of that balance against the outflow behind it, and Q32 Bio Inc. scores 42/100 among other emerging companies.
Q32 Bio Inc. had 15M shares outstanding at the end of fiscal year 2025. Dilution ranks emerging companies on how fast that count has grown over three years, where a slower rise is the better one, and Q32 Bio Inc. scores 86/100 among other emerging companies.
Q32 Bio Inc. spent $19.2M on research and development in fiscal year 2025, which was 52.0% of its operating costs that year. R&D Intensity ranks emerging companies on the share of operating costs that goes into research, and Q32 Bio Inc. scores 79/100 among other emerging companies.
Q32 Bio Inc. reported revenue of $53.7M in fiscal year 2025, against none in fiscal year 2024. Revenue Progress ranks emerging companies on the three-year path of that line, and Q32 Bio Inc. scores 97/100 among other emerging companies.
Q32 Bio Inc.'s operations used $33.5M of cash in fiscal year 2025, against $67.7M used in fiscal year 2024. Burn Trend ranks emerging companies on which way that figure has moved over three years, and Q32 Bio Inc. scores 21/100 among other emerging companies.
Q32 Bio Inc.'s cash, cash equivalents and investments came to $48.3M at the end of fiscal year 2025, against $19.8M of total liabilities. Balance Sheet ranks emerging companies on that comparison, and Q32 Bio Inc. scores 78/100 among other emerging companies.
Q32 Bio Inc. scores 5.51, well above the 2.99 safe threshold. The score is driven primarily by a large market capitalization ($248.3M) relative to total liabilities ($19.8M). This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Q32 Bio Inc. passes 3 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 2 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), both operating efficiency signals pass.
For every $1 of reported earnings, Q32 Bio Inc. used $1.13 of operating cash (-$33.5M OCF vs $29.8M net income). Earnings that no cash stands behind rest on accounting accruals, which cannot be repeated indefinitely.
Q32 Bio Inc. earns $16.02 in operating income for every $1 of interest expense ($16.9M vs $1.1M). This wide margin provides strong safety for debt servicing, even if earnings decline temporarily.
Key Financial Metrics
Earnings & Revenue
Q32 Bio Inc.'s EBITDA was -$9.0M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 0.6% from the same quarter a year earlier. Against the prior quarter it is down 18.2%.
Q32 Bio Inc. reported -$8.9M in net income in Q2 2026. This represents an increase of 5.7% from the same quarter a year earlier. Against the prior quarter it is down 17.6%.
Q32 Bio Inc. earned -$0.44 per diluted share (EPS) in Q2 2026. Against the prior quarter it is up 18.5%.
Not reported for Q2 2026.
Cash & Balance Sheet
Q32 Bio Inc. held $106.3M in cash as of Q2 2026; long-term debt is not reported for that period.
Not reported for Q2 2026.
Not reported for Q2 2026.
Margins & Returns
Q32 Bio Inc.'s ROE was -8.5% in Q2 2026, measuring profit generated per dollar of shareholder equity. Against the prior quarter it is up 8.0 percentage points.
Not reported for Q2 2026.
Not reported for Q2 2026.
Not reported for Q2 2026.
Capital Allocation
Q32 Bio Inc. invested $4.3M in research and development in Q2 2026. This represents a decrease of 17.5% from the same quarter a year earlier. Against the prior quarter it is up 32.3%.
Not reported for Q2 2026.
Not reported for Q2 2026.
QTTB Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $0-100.0% |
| R&D Expenses | $4.3M-17.5% | $3.2M-54.8% | N/A | $3.6M-75.2% | $5.2M-61.5% | $7.1M-27.6% | N/A | $14.3M+92.2% |
| SG&A Expenses | $4.9M+21.2% | $4.5M-11.8% | N/A | $4.0M-10.0% | $4.0M-11.0% | $5.1M+2.0% | N/A | $4.5M+103.6% |
| Operating Income | -$9.1M+0.6% | -$7.7M+36.8% | N/A | -$7.6M+59.7% | -$9.2M+48.8% | -$12.2M+17.6% | N/A | -$18.8M-141.3% |
| EBITDA | -$9.0M+0.6% | -$7.6M+37.0% | N/A | -$7.5M+60.0% | -$9.1M+49.1% | -$12.1M+17.7% | N/A | -$18.7M-143.1% |
| Interest Expense | -$246K+13.4% | -$192K+48.2% | N/A | -$220K+76.0% | -$284K+73.4% | -$371K-106.1% | N/A | -$917K |
| Income Tax | $0 | $0 | N/A | $0 | $0 | $0 | N/A | $0+100.0% |
| Net Income | -$8.9M+5.7% | -$7.6M+31.0% | N/A | -$7.4M+58.0% | -$9.5M+44.1% | -$11.0M-1172.0% | N/A | -$17.6M-25.4% |
| EPS (Basic) | -$0.44+43.6% | -$0.54+40.0% | $4.71+524.3% | -$0.60+58.9% | -$0.78+45.1% | -$0.90-187.4% | -$1.11-311.1% | -$1.46+96.4% |
| EPS (Diluted) | -$0.44 | -$0.54+40.0% | $4.71+580.6% | -$0.60+58.9% | -$0.78+45.1% | -$0.90+85.8% | -$0.98 | -$1.46 |
| Diluted Shares (Avg) | 20M | 14M+15.6% | N/A | 12M+1.4% | 12M+2.0% | 12M+422.6% | N/A | 12M |
Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit.
QTTB Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $115.9M+75.2% | $63.7M-19.5% | $61.8M-33.1% | $57.8M-44.7% | $66.1M-46.8% | $79.1M-48.1% | $92.3M+96.2% | $104.5M-25.4% |
| Current Assets | $109.6M+88.0% | $57.2M-16.7% | $55.0M-32.8% | $50.8M-45.9% | $58.3M-47.7% | $68.6M-50.3% | $81.9M+185.1% | $93.9M-11.9% |
| Cash & Equivalents | $106.3M+93.8% | $50.8M-22.5% | $48.3M-38.1% | $49.0M-44.9% | $54.8M-43.9% | $65.5M-43.3% | $78.0M+204.3% | $89.1M+145.7% |
| Short-Term Investments | $0 | $0 | $0 | $0 | $0-100.0% | $0-100.0% | $0 | $0-100.0% |
| Long-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $10.0M-87.3% | $17.4M-79.1% | $19.8M-77.2% | $76.2M-11.6% | $78.4M-13.6% | $83.1M-19.8% | $86.7M-62.3% | $86.2M-70.9% |
| Current Liabilities | $5.4M-53.2% | $10.7M-26.8% | $11.3M-31.1% | $11.1M-22.8% | $11.5M-32.9% | $14.6M-55.8% | $16.5M+16.7% | $14.4M-43.1% |
| Non-Current Liabilities | $4.6M-93.2% | $6.7M-90.2% | $8.4M-88.0% | $65.1M-9.4% | $66.8M-9.1% | $68.5M-3.0% | $70.2M-67.5% | $71.9M-73.5% |
| Total Equity | $105.9M+965.6% | $46.3M+1253.8% | $42.0M+640.3% | -$18.4M-200.8% | -$12.2M-136.5% | -$4.0M-108.2% | $5.7M+103.1% | $18.3M+111.7% |
| Retained Earnings | -$221.5M+13.2% | -$212.6M+13.5% | -$205.0M+12.7% | -$262.7M-19.1% | -$255.3M-25.8% | -$245.8M-32.1% | -$234.8M-25.5% | -$220.6M+58.1% |
Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.
QTTB Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$3.1M+71.1% | -$6.3M+49.2% | -$6.2M+45.9% | -$4.2M+78.3% | -$10.7M+52.1% | -$12.5M+14.2% | -$11.4M-6.7% | -$19.5M-222.8% |
| Depreciation & Amortization | $100K0.0% | $90K-24.4% | $90K-25.0% | $100K0.0% | $100K0.0% | $119K-3.3% | $120K-3.2% | $100K0.0% |
| Stock-Based Compensation | $1.7M+33.0% | $1.5M+15.4% | N/A | $1.2M-14.9% | $1.3M-5.1% | $1.3M+221.8% | N/A | $1.4M+359.1% |
| Capital Expenditures | N/A | N/A | $0-100.0% | $0-100.0% | N/A | N/A | $2K | $58K+5700.0% |
| Free Cash Flow | N/A | N/A | -$6.2M+45.9% | -$4.2M+78.4% | N/A | N/A | -$11.4M-6.7% | -$19.6M-223.1% |
| Investing Cash Flow | $0 | $0 | $7.0M+350100.0% | $0-100.0% | $0-100.0% | $0-100.0% | -$2K | $9.9M+994300.0% |
| Financing Cash Flow | $58.6M | $8.8M | -$1.6M-592.7% | -$1.6M-256.8% | N/A | N/A | $317K+317.1% | $997K+232.3% |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
QTTB Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Return on Equity | -8.5% | -16.4% | N/A | N/A | N/A | N/A | N/A | -96.2% |
| Return on Assets | -7.7%+6.6pp | -11.9%+2.0pp | N/A | -12.8%+4.0pp | -14.3%-0.7pp | -14.0%-14.6pp | N/A | -16.8%-6.8pp |
| Current Ratio | 20.30+15.2x | 5.36+0.7x | 4.85-0.1x | 4.57-2.0x | 5.06-1.4x | 4.71+0.5x | 4.97+2.9x | 6.53+2.3x |
| Debt-to-Equity | 0.09 | 0.37 | 0.47-14.8x | N/A | N/A | N/A | 15.27 | 4.71 |
| Asset Turnover | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.000.0x |
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, FCF Margin.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Q32 Bio Inc. QTTB | FY2025 | $53.7M | $29.8M | 55.5% | $248.3M | 67/100 |
| Akari Therapeutics plc AKTX | FY2025 | N/A | -$17.3M | N/A | $18.6M | — |
| Lixte Biotechnology Holdings, Inc. LIXT | FY2025 | N/A | -$6.1M | N/A | $125.4M | — |
| SAB Biotherapeutics, Inc. SABS | FY2025 | $0 | $13.3M | N/A | $263.0M | — |
| Curis Inc CRIS | FY2025 | $9.4M | -$7.6M | -80.3% | $1.7M | 42/100 |
| Exicure, Inc. XCUR | FY2025 | $0 | -$4.9M | N/A | $6.5M | — |
Where Q32 Bio Inc. Ranks
Frequently Asked Questions
What is Q32 Bio Inc.'s annual revenue?
Q32 Bio Inc. (QTTB) reported $53.7M in total revenue for fiscal year 2025. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
Is Q32 Bio Inc. profitable?
Yes, Q32 Bio Inc. (QTTB) reported a net income of $29.8M in fiscal year 2025, with a net profit margin of 55.5%.
What is Q32 Bio Inc.'s EBITDA?
Q32 Bio Inc. (QTTB) had EBITDA of $17.3M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Q32 Bio Inc.'s operating margin?
Q32 Bio Inc. (QTTB) had an operating margin of 31.4% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Q32 Bio Inc.'s net profit margin?
Q32 Bio Inc. (QTTB) had a net profit margin of 55.5% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Q32 Bio Inc.'s return on equity (ROE)?
Q32 Bio Inc. (QTTB) has a return on equity of 70.9% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Q32 Bio Inc.'s free cash flow?
Q32 Bio Inc. (QTTB) recorded an outflow of $33.5M in free cash flow during fiscal year 2025. This represents a 50.5% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Q32 Bio Inc.'s operating cash flow?
Q32 Bio Inc. (QTTB) recorded an outflow of $33.5M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Q32 Bio Inc.'s total assets?
Q32 Bio Inc. (QTTB) had $61.8M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Q32 Bio Inc.'s capital expenditures?
Q32 Bio Inc. (QTTB) reported no capital expenditure during fiscal year 2025.
How much does Q32 Bio Inc. spend on research and development?
Q32 Bio Inc. (QTTB) invested $19.2M in research and development during fiscal year 2025.
What is Q32 Bio Inc.'s current ratio?
Q32 Bio Inc. (QTTB) had a current ratio of 4.85 as of fiscal year 2025, which is generally considered healthy.
What is Q32 Bio Inc.'s debt-to-equity ratio?
Q32 Bio Inc. (QTTB) had a debt-to-equity ratio of 0.47 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Q32 Bio Inc.'s return on assets (ROA)?
Q32 Bio Inc. (QTTB) had a return on assets of 48.2% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Q32 Bio Inc.'s P/E ratio?
Q32 Bio Inc. (QTTB) trades at 8.3x earnings, its market capitalization divided by net income of $29.8M net income, FY2025. The market capitalization is $248.3M as of Oct 9, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Q32 Bio Inc.'s price-to-sales ratio?
Q32 Bio Inc. (QTTB) trades at 4.6x sales, its market capitalization divided by revenue of $53.7M revenue, FY2025. The market capitalization is $248.3M as of Oct 9, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
How does Q32 Bio Inc.'s liquidity compare with its operating cash outflow?
At the end of fiscal year 2025, Q32 Bio Inc. (QTTB) held $48.3M in cash, cash equivalents and investments, and reported an operating cash outflow of $33.5M over that year. Dividing the one by the other, the reported balance equals about 17 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
What is Q32 Bio Inc.'s Altman Z-Score?
Q32 Bio Inc. (QTTB) has an Altman Z-Score of 5.51, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Q32 Bio Inc.'s Piotroski F-Score?
Q32 Bio Inc. (QTTB) has a Piotroski F-Score of 3 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Q32 Bio Inc.'s earnings high quality?
For every $1 of reported earnings, Q32 Bio Inc. (QTTB) used $1.13 of operating cash (-$33.5M OCF vs $29.8M net income). Earnings that no cash stands behind rest on accounting accruals, which cannot be repeated indefinitely. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Q32 Bio Inc. cover its interest payments?
Q32 Bio Inc. (QTTB) has an interest coverage ratio of 16.02x, meaning it can comfortably cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Q32 Bio Inc.?
Q32 Bio Inc. (QTTB) scores 67 out of 100 on our Financial Health Score, indicating strong standing within its emerging companies peer group. The score is a 0-100 composite of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.